These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26050556)

  • 1. Herbs to curb cyclic nucleotide phosphodiesterase and their potential role in Alzheimer's disease.
    Kumar A; Sharma V; Singh VP; Kaundal M; Gupta MK; Bariwal J; Deshmukh R
    Mech Ageing Dev; 2015 Jul; 149():75-87. PubMed ID: 26050556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer's Disease.
    Sharma VK; Singh TG; Singh S
    Curr Drug Targets; 2020; 21(13):1371-1384. PubMed ID: 32718286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
    Xi M; Sun T; Chai S; Xie M; Chen S; Deng L; Du K; Shen R; Sun H
    Eur J Med Chem; 2022 Mar; 232():114170. PubMed ID: 35144038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterases: Regulators of cyclic nucleotide signals and novel molecular target for movement disorders.
    Sharma S; Kumar K; Deshmukh R; Sharma PL
    Eur J Pharmacol; 2013 Aug; 714(1-3):486-97. PubMed ID: 23850946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview.
    Heckman PR; Wouters C; Prickaerts J
    Curr Pharm Des; 2015; 21(3):317-31. PubMed ID: 25159073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDE and cognitive processing: beyond the memory domain.
    Heckman PR; Blokland A; Ramaekers J; Prickaerts J
    Neurobiol Learn Mem; 2015 Mar; 119():108-22. PubMed ID: 25464010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From Age-Related Cognitive Decline to Alzheimer's Disease: A Translational Overview of the Potential Role for Phosphodiesterases.
    Heckman PRA; Blokland A; Prickaerts J
    Adv Neurobiol; 2017; 17():135-168. PubMed ID: 28956332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of Compartmentalised Cyclic Nucleotide Signalling via Local Inhibition of Phosphodiesterase Activity.
    Brescia M; Zaccolo M
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27706091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Phosphodiesterase-2 in Psychiatric and Neurodegenerative Disorders.
    Zhang C; Lueptow LM; Zhang HT; O'Donnell JM; Xu Y
    Adv Neurobiol; 2017; 17():307-347. PubMed ID: 28956338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Prickaerts J; Heckman PRA; Blokland A
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1033-1048. PubMed ID: 28772081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders.
    Xu Y; Zhang HT; O'Donnell JM
    Handb Exp Pharmacol; 2011; (204):447-85. PubMed ID: 21695652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cancer with phosphodiesterase inhibitors.
    Savai R; Pullamsetti SS; Banat GA; Weissmann N; Ghofrani HA; Grimminger F; Schermuly RT
    Expert Opin Investig Drugs; 2010 Jan; 19(1):117-31. PubMed ID: 20001559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations.
    Heckman PRA; Blokland A; Bollen EPP; Prickaerts J
    Neurosci Biobehav Rev; 2018 Apr; 87():233-254. PubMed ID: 29454746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
    Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
    J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases.
    Li Q; Liao Q; Qi S; Huang H; He S; Lyu W; Liang J; Qin H; Cheng Z; Yu F; Dong X; Wang Z; Han L; Han Y
    Eur J Med Chem; 2024 May; 271():116386. PubMed ID: 38614063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer's disease.
    Gulisano W; Tropea MR; Arancio O; Palmeri A; Puzzo D
    Neuropharmacology; 2018 Aug; 138():151-159. PubMed ID: 29885420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats.
    Rutten K; Van Donkelaar EL; Ferrington L; Blokland A; Bollen E; Steinbusch HW; Kelly PA; Prickaerts JH
    Neuropsychopharmacology; 2009 Jul; 34(8):1914-25. PubMed ID: 19262466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.
    Wu Y; Li Z; Huang YY; Wu D; Luo HB
    J Med Chem; 2018 Jul; 61(13):5467-5483. PubMed ID: 29363967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
    de Vente J; Markerink-van Ittersum M; Vles JS
    J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.